XRP
All compounds
Growth FactorMuscle

IGF-1 LR3

Long R3 Insulin-like Growth Factor

Typical Dose
20–80 mcg
Route
Injectable
Variants
1mg

Overview

What is IGF-1 LR3?

IGF-1 LR3 is a modified IGF-1 analog with a longer half-life and reduced binding to IGFBPs, supporting muscle hyperplasia and recovery research.

Mechanism of Action

Binds IGF-1R on muscle cells, activating PI3K/Akt/mTOR signaling for protein synthesis and satellite cell proliferation.

Key Benefits

  • Muscle hypertrophy and hyperplasia
  • Nutrient partitioning
  • Recovery acceleration

Research Indications

Muscle growth researchMost Effective
RecoveryEffective
Fat partitioningModerate

Research Protocols

Disclaimer

These are commonly discussed research protocols and not medical advice. Consult a healthcare provider before use.

GoalDoseFrequencyRoute
Conservative20 mcg1x dailySubcutaneous near worked muscle
Standard starting dose40 mcg1x dailySubcutaneous
Typical maintenance50 mcg1x daily 5/7 daysSubcutaneous
Maximum80 mcg1x dailySubcutaneous

Peptide Interactions

GH peptides
Synergistic
Insulin
Hypoglycemia risk
Monitor

Side Effects & Safety

Common Side Effects

  • Hypoglycemia
  • Numbness
  • Tissue hyperplasia (organ growth) at high doses

Safety Guidelines

  • For laboratory research use only — not for human consumption
  • Store reconstituted vials at 2–8°C, use within 30 days
  • Rotate injection sites to avoid local irritation
  • Discontinue and consult a clinician if adverse reactions occur

Quality Indicators

  • ≥95% purity verified by HPLC
  • Third-party tested for sterility
  • Lyophilized in sealed multi-dose vial
  • Bacteriostatic water reconstitution
  • Refrigerated cold-chain shipping

What to Expect

  1. 1
    Week 1–2
    Pump and recovery feel
  2. 2
    Week 3–4
    Visible hyperplasia signals
  3. 3
    Week 5–8
    Sustained anabolic response

Need a different compound?

Browse all peptides